1.08
0.00%
0.00
Schlusskurs vom Vortag:
$1.08
Offen:
$1.07
24-Stunden-Volumen:
12,606
Relative Volume:
0.05
Marktkapitalisierung:
$12.46M
Einnahmen:
$996.00K
Nettoeinkommen (Verlust:
$-6.09M
KGV:
-2.0377
EPS:
-0.53
Netto-Cashflow:
$-9.76M
1W Leistung:
-6.09%
1M Leistung:
+25.58%
6M Leistung:
-38.29%
1J Leistung:
-52.21%
Therapeuticsmd Inc Stock (TXMD) Company Profile
Firmenname
Therapeuticsmd Inc
Sektor
Telefon
561-961-1900
Adresse
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
Vergleichen Sie TXMD mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
TXMD
Therapeuticsmd Inc
|
1.08 | 12.46M | 996.00K | -6.09M | -9.76M | -0.53 |
ZTS
Zoetis Inc
|
170.90 | 77.10B | 9.15B | 2.43B | 2.31B | 5.32 |
HLN
Haleon Plc Adr
|
9.47 | 42.82B | 14.26B | 1.55B | 0 | 0.3383 |
TAK
Takeda Pharmaceutical Co Adr
|
13.39 | 42.45B | 30.27B | 1.93B | 3.45B | 0.6044 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.73 | 20.09B | 16.77B | -959.00M | 1.37B | -0.85 |
NBIX
Neurocrine Biosciences Inc
|
151.82 | 15.37B | 2.24B | 385.90M | 440.10M | 3.73 |
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2020-08-07 | Herabstufung | Jefferies | Hold → Underperform |
2020-05-19 | Herabstufung | JP Morgan | Overweight → Neutral |
2019-12-02 | Eingeleitet | Guggenheim | Buy |
2019-10-17 | Eingeleitet | H.C. Wainwright | Buy |
2019-04-30 | Fortgesetzt | Noble Capital Markets | Outperform |
2018-06-15 | Eingeleitet | JP Morgan | Overweight |
2017-09-08 | Eingeleitet | Morgan Stanley | Equal-Weight |
2017-07-11 | Hochstufung | Oppenheimer | Perform → Outperform |
2017-05-09 | Herabstufung | Oppenheimer | Outperform → Perform |
2016-11-22 | Fortgesetzt | Jefferies | Buy |
2016-11-22 | Eingeleitet | Oppenheimer | Outperform |
2016-11-07 | Fortgesetzt | Guggenheim | Buy |
2016-04-04 | Eingeleitet | Goldman | Buy |
2015-12-08 | Bestätigt | Jefferies | Buy |
2015-12-08 | Bestätigt | Stifel | Buy |
2015-09-21 | Bestätigt | Jefferies | Buy |
2015-06-09 | Eingeleitet | Guggenheim | Buy |
2014-07-08 | Eingeleitet | FBR Capital | Outperform |
2014-04-17 | Bestätigt | Noble Financial | Buy |
2014-01-28 | Bestätigt | Noble Financial | Buy |
Alle ansehen
Therapeuticsmd Inc Aktie (TXMD) Neueste Nachrichten
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD) - Defense World
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock outperforms competitors despite losses on the day - MarketWatch
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
TherapeuticsMD (NASDAQ:TXMD) Coverage Initiated at StockNews.com - Defense World
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors - MarketWatch
3 Promising US Penny Stocks With Over $9M Market Cap - Simply Wall St
StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD) - Defense World
TXMD stock touches 52-week low at $1.04 amid market challenges - Investing.com Nigeria
TXMD stock touches 52-week low at $1.04 amid market challenges By Investing.com - Investing.com South Africa
TherapeuticsMD Inc. stock remains steady Friday, still outperforms market - MarketWatch
TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com - Defense World
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
TXMD stock touches 52-week low at $1.13 amid market challenges By Investing.com - Investing.com South Africa
TXMD stock touches 52-week low at $1.13 amid market challenges - Investing.com India
TherapeuticsMD Inc. stock remains steady Thursday, still outperforms market - MarketWatch
TherapeuticsMD holds annual meeting, elects directors - Investing.com
TherapeuticsMD holds annual meeting, elects directors By Investing.com - Investing.com Canada
TherapeuticsMD (STU:29TA) 3-Year FCF Growth Rate : 57.70% (As of Sep. 2024) - GuruFocus.com
Finanzdaten der Therapeuticsmd Inc-Aktie (TXMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Therapeuticsmd Inc-Aktie (TXMD) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Collins Cooper C. | Director |
Aug 21 '24 |
Buy |
1.70 |
1,200 |
2,039 |
47,922 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):